THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.8] ID: TIP-MED-000240

Silodosin (Uroselective Alpha-1A Blocker for BPH)

Active Ingredient / Scientific Identity: Silodosin • Class: Highly Uroselective Alpha-1A Adrenergic Receptor Antagonist

⚖️ Compare Profile
Generic / Entity NameSilodosin (Uroselective Alpha-1A Blocker for BPH) ([12.8])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassHighly Uroselective Alpha-1A Adrenergic Receptor Antagonist
Available Dosage FormsCapsule / Tablet: 4 mg, 8 mg; FDC with Dutasteride 0.5 mg.
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Moderate CKD (eGFR 30-50 mL/min): Reduce dose to 4 mg once daily with food. Severe CKD (eGFR <30 mL/min): Contraindica
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Silodosin (Uroselective Alpha-1A Blocker for BPH) (TIP-MED-000240, Reference Code [12.8]) is classified under Urological & Renal Stone Medicines (Ch 12) as a Highly Uroselective Alpha-1A Adrenergic Receptor Antagonist. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.8], p. 158): Silofast, Rapilif, Geripod, Sildoo (FDC with Dutasteride: Silofast-D, Rapilif-D) — Strengths & Dosage Forms: Capsule / Tablet: 4 mg, 8 mg; FDC with Dutasteride 0.5 mg.
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.8], p. 158): Silofast, Rapilif, Geripod, Sildoo (FDC with Dutasteride: Silofast-D, Rapilif-D) — Strengths & Dosage Forms: Capsule / Tablet: 4 mg, 8 mg; FDC with Dutasteride 0.5 mg.
Dosage Forms & Available Strengths:
Capsule / Tablet: 4 mg, 8 mg; FDC with Dutasteride 0.5 mg.
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Ultra-high selectivity for prostatic, bladder-neck, and urethral alpha-1A receptors over vascular alpha-1B receptors (162:1 selectivity) -> relaxes smooth muscle outflow resistance with minimal orthostatic blood pressure drop.

4. Therapeutic Indications & Evidence-Supported Uses

  • Symptomatic benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: 8 mg PO once daily with a meal. • Paediatric: Not indicated in children.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Moderate CKD (eGFR 30-50 mL/min): Reduce dose to 4 mg once daily with food. Severe CKD (eGFR <30 mL/min): Contraindicated. • Hepatic: Mild-to-moderate: No adjustment. Severe hepatic impairment (Child-Pugh C): Contraindicated.
Elimination & Renal Adjustment:
Renal: Moderate CKD (eGFR 30-50 mL/min): Reduce dose to 4 mg once daily with food. Severe CKD (eGFR <30 mL/min): Contraindicated. • Hepatic: Mild-to-moderate: No adjustment. Severe hepatic impairment (Child-Pugh C): Contraindicated.
Hepatic Impairment Considerations:
Renal: Moderate CKD (eGFR 30-50 mL/min): Reduce dose to 4 mg once daily with food. Severe CKD (eGFR <30 mL/min): Contraindicated. • Hepatic: Mild-to-moderate: No adjustment. Severe hepatic impairment (Child-Pugh C): Contraindicated.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Severe renal impairment (CrCl <30 mL/min); severe hepatic impairment; concomitant strong CYP3A4 or P-gp inhibitors (Ketoconazole, Itraconazole, Ritonavir, Clarithromycin). • Precautions: Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery (inform ophthalmologist even if stopped months earlier); causes reversible retrograde ejaculation/anejaculation in ~28% of men.

Key Clinical Precautions: Renal: Moderate CKD (eGFR 30-50 mL/min): Reduce dose to 4 mg once daily with food. Severe CKD (eGFR <30 mL/min): Contraindicated. • Hepatic: Mild-to-moderate: No adjustment. Severe hepatic impairment (Child-Pugh C): Contraindicated.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Retrograde ejaculation (orgasm with reduced/absent seminal emission), dizziness, nasal congestion, diarrhoea.
  • Intraoperative Floppy Iris Syndrome (IFIS), orthostatic syncope.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Strong CYP3A4 inhibitors (Ketoconazole, Itraconazole, Clarithromycin) -> 3-fold surge in silodosin levels (CONTRAINDICATED); PDE5 inhibitors (Sildenafil, Tadalafil) -> postural hypotension

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Always take WITH a meal (taking on an empty stomach increases peak levels and dizziness); inform your eye surgeon before cataract surgery; reduced/absent semen volume during ejaculation is harmless and reversible.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM | Compendia: IP 2026 / NFI 7th Ed 2026 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Capsule / Tablet: 4 mg, 8 mg; FDC with Dutasteride 0.5 mg.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.8] (p. 158)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.